Compare Crispr Therapeutics AG (CRSP) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ArcelorMittal SA — how do they compare? Crispr Therapeutics AG trades at $50.73 (market cap $5.06B), while ArcelorMittal SA trades at $63.13 (market cap $47.06B). The key difference: ArcelorMittal SA is far larger — about 9.3× Crispr Therapeutics AG's market cap, and ArcelorMittal SA pays a 0.96% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and ArcelorMittal SA for 36 Days on average.
| CRSP | MT | |
|---|---|---|
Market Cap | $5.06B | $47.06B |
Volume | 1,678,371 | 1,545,197 |
Sector | Health | Basic Materials |
52-Week High | $74.92 | $78.74 |
52-Week Low | $44.34 | $36.91 |
Typical Hold Time | 77 Days | 36 Days |
Enterprise Value | $3.48B | $56.63B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.
While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.
ArcelorMittal (MT) trades at $61.30, down 5.97% amid bearish technical signals and recent Ukraine plant impairment concerns. The stock shows mixed fundamentals with attractive valuation metrics (P/S 0.76, P/B 0.86) but declining revenue trends from $79.8B in 2022 to $61.4B in 2025. Recent Q2 2026 earnings missed expectations, though management expects stronger second-half performance supported by European demand recovery and strategic investments.
While analyst consensus remains bullish with a $74.33 price target (52% buy ratings), significant risks include ongoing Ukraine operations disruption, $1B impairment charge, and China demand weakness. The current price near support levels presents potential entry point for value investors, but requires careful monitoring of European recovery execution and geopolitical stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
